参考文献/References:
[1] 廖琴平, 杨曦. 子宫内膜癌筛查及早期诊断的现状及展望[J]. 实用妇产科杂志, 2015, 31(7):481-484. DOI:1003-6946(2015)07-481-0. Liao QP, Yang X. Current status and Prospect of screening andearly diagnosis of endometrial cancer[J]. J Pract Obstet Gynecol, 2015, 31(7):481-484.
[2] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4):225-249. DOI:10.3322/caac.20006.
[3] Nakamura K, Kodama J, Okumura Y, et al. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer[J]. Int J Gynecol Cancer, 2010, 20(1):110-115. DOI:10.1111/IGC.0b013e3181c3a288.
[4] Nakamura K, Hongo A, Kodama J, et al. The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer[J]. Gynecol Oncol, 2011, 123(1):82-87. DOI:10.1016/j.ygyno.2011.06.026.
[5] Lee HJ, Ahn BC, Hong CM, et al. Preoperative risk stratification using 18F-FDG PET/CT in women with endometrial cancer[J]. Nuklearmedizin, 2011, 50(5):204-213. DOI:10.3413/nukmed-0375-10-12.
[6] Kitajima K, Kita M, Suzuki K, et al. Prognostic significance of SUVmax (maximum standardized uptake value) measured by[18F]FDG PET/CT in endometrial cancer[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5):840-845. DOI:10.1007/s00259-011-2057-9.
[7] Antonsen SL, Jensen LN, Loft A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer-a multicenter prospective comparative study[J]. Gynecol Oncol, 2013, 128(2):300-308. DOI:10.1016/j.ygyno.2013.01.019.
[8] Walentowicz-Sadlecka M, Malkowski B, Walentowicz P, et al. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients[J/OL]. Biomed Res Int, 2014, 2014:234813[2017-11-28]. https://www.hindawi.com/journals/bmri/2014/234813/. DOI:10.1155/2014/234813.
[9] Ghooshkhanei H, Treglia G, Sabouri G, et al. Risk stratification and prognosis determination using 18F-FDG PET imaging in endometrial cancer patients:a systematic review and meta-analysis[J]. Gynecol Oncol, 2014,132(3):669-676. DOI:10.1016/j.ygyno.2014.01.039.
[10] Pak K, Cheon GJ, Nam HY, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer:a systematic review and meta-analysis[J]. J Nucl Med, 2014, 55(6):884-890. DOI:10.2967/jnumed.113.133801.
[11] Liu FY, Chao A, Lai CH, et al. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma[J]. Gynecol Oncol, 2012, 125(3):566-571. DOI:10.1016/j.ygyno.2012. 03.021.
[12] Chung HH, Lee I, Kim HS, et al. Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer[J]. Gynecol Oncol, 2013, 130(3):446-451. DOI:10.1016/j.ygyno.2013.06.021.
[13] Crivellaro C, Signorelli M, Guerra L, et al. Tailoring systematic lymphadenectomy in high-risk clinica l early stage endometrial cancer:the role of 18F-FDG PET/CT[J]. Gynecol Oncol, 2013, 130(2):306-311. DOI:10.1016/j.ygyno.2013.05.011.
[14] Shim SH, Kim DY, Lee DY, et al. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer[J]. BJOG, 2014, 121(9):1097-1106. DOI:10.1111/1471-0528. 12543.
[15] Sudo S, Hattori N, Manabe O, et al. FDG PET/CT diagnostic criteria may need adjustment based on MRI to estimate the presurgical risk of extrapelvic infiltration in patients with uterine endometrial cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(5):676-684. DOI:10.1007/s00259-014-2964-7.
[16] Kitajima K, Suenaga Y, Ueno Y, et al. Preoperative risk stratification using metabolic parameters of 18F-FDG PET/CT in patients with endometrial cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(8):1268-1275. DOI:10.1007/s00259-015-3037-2.
[17] Benedetti PP, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma:randomized clinical trial[J]. J Natl Cancer Inst, 2008, 100(23):1707-1716. DOI:10.1093/jnci/djn397.
[18] Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial):a randomised study[J]. Lancet, 2009, 373(9658):125-136. DOI:10.1016/S0140-6736(08)61766-3.
[19] Kim HJ, Cho A, Yun M, et al. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer[J]. Ann Nucl Med, 2016, 30(2):104-113. DOI:10.1007/s12149-015-1037-8.
[20] Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer[J]. Eur Radiol, 2009, 19(6):1529-1536. DOI:10.1007/s00330-008-1271-8.
[21] Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer:diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27(1):16-41. DOI:10.1093/annonc/mdv484.
[22] Tsujikawa T, Yoshida Y, Kudo T, et al. Functional images reflect aggressiveness of endometrial carcinoma:estrogen receptor expression combined with 18F-FDG PET[J]. J Nucl Med, 2009, 50(10):1598-1604. DOI:10.2967/jnumed.108.060145.
[23] 张凤仙, 张建, 陈素芸, 等. 18F-FDG PET/CT显像SUVmax对子宫内膜癌术前浸润及转移的评估价值[J]. 中华核医学与分子影像杂志, 2017, 37(2):75-80. DOI:10.3760/cma.j.issn.2095-2848. 2017. 02.003. Zhang FX, Zhang J, Chen SY, et al. Value of 18F-FDG PET/CT SUVmax for preoperative assessment of primary tumor infiltration and metastases in patients with endometrial cancer[J]. Chin J Nucl Med Mol Imaging, 2017, 37(2):75-80.
[24] Haldorsen IS, Salvesen HB. What is the best preoperative imaging for endometrial cancer?[J]. Curr Oncol Rep, 2016, 18(4):25. DOI:10.1007/s11912-016-0506-0.
[25] Wright JD, Barrena MNI, Sehouli J, et al. Contemporary management of endometrial cancer[J]. Lancet, 2012, 379(9823):1352-1360. DOI:10.1016/S0140-6736(12)60442-5.
相似文献/References:
[1]薛艳,安瑞芳.放射免疫显像在妇科肿瘤中的研究与应用[J].国际放射医学核医学杂志,2006,30(1):36.
XUE Yan,AN Rui-fang.A research on radioimmunoimaging and its application in diagnosis of gynecological tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):36.
[2]陈挺,张宏,田梅.18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值[J].国际放射医学核医学杂志,2018,(3):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
Chen Ting,Zhang Hong,Tian Mei.Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
[3]杜芬,胡珊,梁梦,等.18F-FDG PET/CT显像在甲状腺偶发瘤良恶性诊断中的研究进展[J].国际放射医学核医学杂志,2018,(3):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
Du Fen,Hu Shan,Liang Meng,et al.Development in the diagnosis of benign and malignant thyroid incidentalomas by 18F-FDG PET/CT imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
[4]高之晔,韩星敏.放射性核素标记的胆碱在PET/CT肿瘤显像中的应用[J].国际放射医学核医学杂志,2018,(3):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
Gao Zhiye,Han Xingmin.Application of radionuclide-labeled choline in PET/CT tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
[5]孙晓琰,常城,雷贝,等.18F-FDG PET/CT在肺癌性淋巴管病的影像学特征及诊断价值[J].国际放射医学核医学杂志,2018,(4):295.[doi:10.3760/cma.j.issn.1673-4114.2018.04.001]
Sun Xiaoyan,Chang Cheng,Lei Bei,et al.Imaging features and diagnostic value of 18F-FDG PET/CT in pulmonary lymphangitic carcinomatosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):295.[doi:10.3760/cma.j.issn.1673-4114.2018.04.001]
[6]段晓蓓,陈相猛,黄斌豪,等.18F-FDG PET/CT显像在肾上腺转移瘤中的诊断价值和预测分析[J].国际放射医学核医学杂志,2018,(4):307.[doi:10.3760/cma.j.issn.1673-4114.2018.04.003]
Duan Xiaobei,Chen Xiangmeng,Huang Binhao,et al.18F-FDG PET/CT diagnostic value and predictive analysis in adrenal metastasis lesions[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):307.[doi:10.3760/cma.j.issn.1673-4114.2018.04.003]
[7]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[8]谭延林,董楚宁,王云华.18F-FDG PET/CT在肺癌疗效评估中的价值[J].国际放射医学核医学杂志,2018,(4):357.[doi:10.3760/cma.j.issn.1673-4114.2018.04.013]
Tan Yanlin,Dong Chuning,Wang Yunhua.The value of 18F-FDG PET/CT on evaluating therapeutic effect in the treatment of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):357.[doi:10.3760/cma.j.issn.1673-4114.2018.04.013]
[9]刘道佳,吴君心,唐明灯,等.18F-FLT PET/CT显像评估复发脑胶质瘤患者预后的价值[J].国际放射医学核医学杂志,2018,(5):403.[doi:10.3760/cma.j.issn.1673-4114.2018.05.003]
Liu Daojia,Wu Junxin,Tang Mingdeng,et al.Prognostic value of 18F-FLT PET/CT imaging in patients with recurrent gliomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):403.[doi:10.3760/cma.j.issn.1673-4114.2018.05.003]
[10]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]